tamoxifen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2561 10540-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tamoxifen
  • tamoxifen citrate
  • tamoxifene
  • tamoxifene citrate
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
  • Molecular weight: 371.52
  • Formula: C26H29NO
  • CLOGP: 6.82
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.56
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.18 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,JAK3,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 58
kinase-selectivity-class CDK4,PDK4 2
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1977 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 2269.44 12.21 739 45210 24766 90557732
Malignant neoplasm progression 2106.56 12.21 1043 44906 105827 90476671
Metastases to liver 1297.98 12.21 504 45445 28303 90554195
Metastases to lung 763.50 12.21 292 45657 15699 90566799
Breast cancer recurrent 722.37 12.21 215 45734 5288 90577210
Metastases to lymph nodes 617.97 12.21 230 45719 11459 90571039
Disease progression 598.22 12.21 551 45398 156064 90426434
Breast cancer metastatic 550.13 12.21 227 45722 14905 90567593
Neoplasm progression 481.67 12.21 293 45656 44193 90538305
Breast cancer 309.83 12.21 240 45709 53521 90528977
Osteonecrosis of jaw 298.78 12.21 207 45742 38896 90543602
Metastasis 285.43 12.21 110 45839 6027 90576471
Metastases to spine 240.14 12.21 85 45864 3658 90578840
Metastases to central nervous system 233.12 12.21 132 45817 17410 90565088
Hot flush 190.13 12.21 190 45759 59298 90523200
Metastases to pleura 180.54 12.21 59 45890 1985 90580513
Neuropathy peripheral 178.93 12.21 279 45670 136691 90445807
Endometrial hyperplasia 176.54 12.21 49 45900 930 90581568
Tumour marker increased 174.07 12.21 76 45873 5731 90576767
Bone lesion 172.89 12.21 78 45871 6359 90576139
Neutropenia 172.05 12.21 363 45586 224541 90357957
PIK3CA-activated mutation 170.92 12.21 50 45899 1154 90581344
Bone disorder 166.33 12.21 118 45831 23002 90559496
Uterine polyp 163.71 12.21 58 45891 2502 90579996
Second primary malignancy 162.41 12.21 87 45862 10291 90572207
Systemic lupus erythematosus 150.76 12.21 8 45941 361888 90220610
Osteonecrosis 148.62 12.21 116 45833 26125 90556373
Glossodynia 148.44 12.21 3 45946 321776 90260722
Endometrial cancer 147.75 12.21 59 45890 3553 90578945
Acute myeloid leukaemia 147.69 12.21 105 45844 20535 90561963
Bone pain 140.24 12.21 165 45784 61818 90520680
Metastases to skin 138.81 12.21 49 45900 2091 90580407
Synovitis 132.16 12.21 9 45940 329743 90252755
Wound 122.20 12.21 8 45941 302972 90279526
Contraindicated product administered 121.95 12.21 11 45938 320128 90262370
Carbohydrate antigen 15-3 increased 119.02 12.21 43 45906 1964 90580534
Hormone receptor positive breast cancer 117.80 12.21 34 45915 747 90581751
Joint swelling 117.76 12.21 54 45895 503246 90079252
Palmar-plantar erythrodysaesthesia syndrome 117.32 12.21 104 45845 27919 90554579
Hepatic lesion 116.14 12.21 57 45892 5616 90576882
Therapeutic product effect decreased 109.98 12.21 8 45941 277563 90304935
Metastases to the mediastinum 109.88 12.21 31 45918 626 90581872
Rheumatoid arthritis 107.26 12.21 26 45923 362588 90219910
Pseudocirrhosis 107.19 12.21 33 45916 911 90581587
Metastases to peritoneum 104.18 12.21 48 45901 4107 90578391
Pericarditis 103.64 12.21 9 45940 270142 90312356
Death 102.22 12.21 480 45469 456071 90126427
Sarcoma uterus 102.10 12.21 18 45931 27 90582471
Osteolysis 101.67 12.21 45 45904 3505 90578993
Endometrial hypertrophy 101.58 12.21 25 45924 289 90582209
Hepatic enzyme increased 97.12 12.21 31 45918 360705 90221793
Lymphoedema 96.17 12.21 69 45880 13684 90568814
Device related thrombosis 95.48 12.21 37 45912 2056 90580442
Infusion related reaction 95.47 12.21 46 45903 416734 90165764
Hysteroscopy 94.01 12.21 17 45932 32 90582466
Maternal exposure during pregnancy 93.35 12.21 33 45916 360030 90222468
Recurrent cancer 93.11 12.21 38 45911 2421 90580077
Maculopathy 92.41 12.21 38 45911 2468 90580030
Irritable bowel syndrome 91.62 12.21 3 45946 207445 90375053
Ejection fraction decreased 91.59 12.21 88 45861 26165 90556333
Disease recurrence 89.78 12.21 103 45846 37550 90544948
Ascites 88.51 12.21 115 45834 47625 90534873
Metastases to pelvis 86.54 12.21 25 45924 551 90581947
Pleural effusion 85.78 12.21 181 45768 111810 90470688
Uterine cancer 83.85 12.21 45 45904 5340 90577158
Invasive ductal breast carcinoma 83.27 12.21 51 45898 7767 90574731
Pulmonary mass 83.00 12.21 87 45862 28685 90553813
Folliculitis 80.62 12.21 6 45943 204347 90378151
Lymphadenopathy 79.82 12.21 107 45842 45668 90536830
Tonsillar disorder 79.79 12.21 28 45921 1174 90581324
Abdominal discomfort 79.45 12.21 75 45874 477253 90105245
Psoriatic arthropathy 79.00 12.21 11 45938 228324 90354174
Muscle injury 76.46 12.21 3 45946 176651 90405847
Swelling 75.59 12.21 61 45888 418997 90163501
Haematotoxicity 74.43 12.21 57 45892 12478 90570020
Arthropathy 72.96 12.21 48 45901 366194 90216304
Metastatic neoplasm 71.53 12.21 39 45910 4776 90577722
Retinopathy 70.83 12.21 35 45914 3499 90578999
Nasal disorder 70.16 12.21 34 45915 3258 90579240
Endometrial atrophy 68.95 12.21 14 45935 60 90582438
Ovarian hyperstimulation syndrome 66.97 12.21 40 45909 5822 90576676
Fibromyalgia 66.69 12.21 12 45937 206257 90376241
Metastases to chest wall 65.92 12.21 21 45928 650 90581848
Hypertriglyceridaemia 65.53 12.21 44 45905 7845 90574653
Excessive eye blinking 65.25 12.21 25 45924 1347 90581151
Pulmonary embolism 65.18 12.21 179 45770 130641 90451857
Hypersensitivity 65.05 12.21 81 45868 454596 90127902
Blood uric acid decreased 64.88 12.21 22 45927 831 90581667
Pseudocellulitis 64.85 12.21 15 45934 130 90582368
Malignant pleural effusion 64.34 12.21 31 45918 2933 90579565
Blister 61.70 12.21 26 45923 254972 90327526
Exposure during pregnancy 61.50 12.21 22 45927 238388 90344110
Eosinophil percentage increased 61.16 12.21 22 45927 992 90581506
Type 2 diabetes mellitus 59.22 12.21 15 45934 203229 90379269
Acute promyelocytic leukaemia 58.85 12.21 22 45927 1107 90581391
Breast mass 58.39 12.21 44 45905 9403 90573095
Wheezing 58.04 12.21 24 45925 238056 90344442
Uterine leiomyoma 57.16 12.21 46 45903 10818 90571680
Endocervical curettage 55.98 12.21 9 45940 4 90582494
Blood cholesterol increased 55.72 12.21 18 45931 207994 90374504
Metastases to thorax 54.94 12.21 15 45934 267 90582231
Breast cancer female 54.01 12.21 51 45898 14835 90567663
Mobility decreased 53.91 12.21 30 45919 250704 90331794
Invasive lobular breast carcinoma 53.45 12.21 20 45929 1009 90581489
Nasopharyngitis 52.68 12.21 78 45871 407026 90175472
Endometriosis 52.26 12.21 35 45914 6213 90576285
Sinusitis 51.30 12.21 59 45890 343029 90239469
Eastern Cooperative Oncology Group performance status worsened 50.50 12.21 23 45926 1916 90580582
Product use issue 50.13 12.21 56 45893 329863 90252635
Condition aggravated 50.12 12.21 146 45803 595399 89987099
Left ventricular dilatation 49.99 12.21 17 45932 648 90581850
Drug hypersensitivity 49.79 12.21 100 45849 463509 90118989
Ovarian cancer 49.73 12.21 35 45914 6732 90575766
Recall phenomenon 49.63 12.21 18 45931 831 90581667
Acquired gene mutation 49.23 12.21 20 45929 1259 90581239
Endometrial thickening 48.88 12.21 16 45933 541 90581957
Tooth extraction 48.72 12.21 43 45906 11470 90571028
Contusion 48.56 12.21 34 45915 251182 90331316
Amenorrhoea 48.05 12.21 43 45906 11679 90570819
Lymphadenopathy mediastinal 48.01 12.21 26 45923 3141 90579357
Dural arteriovenous fistula 47.34 12.21 9 45940 25 90582473
Neoplasm recurrence 47.31 12.21 26 45923 3233 90579265
Drug ineffective 47.30 12.21 462 45487 1383836 89198662
Discomfort 46.90 12.21 42 45907 274293 90308205
Treatment failure 46.82 12.21 51 45898 303877 90278621
Oestradiol abnormal 46.59 12.21 10 45939 59 90582439
Injury 46.34 12.21 21 45928 197328 90385170
Polyneuropathy 46.25 12.21 53 45896 19288 90563210
Peripheral swelling 46.18 12.21 87 45862 413019 90169479
Vitreous detachment 46.03 12.21 23 45926 2355 90580143
Metastases to spinal cord 45.37 12.21 13 45936 278 90582220
Mucosal inflammation 45.11 12.21 94 45855 57531 90524967
Pleural disorder 44.94 12.21 16 45933 700 90581798
Spinal cord compression 44.69 12.21 29 45920 4882 90577616
Lymphangiosis carcinomatosa 44.07 12.21 20 45929 1652 90580846
Bronchomalacia 43.78 12.21 12 45937 217 90582281
Peritoneal disorder 42.72 12.21 15 45934 630 90581868
Hydrothorax 42.69 12.21 17 45932 1016 90581482
Metastases to ovary 41.69 12.21 14 45935 513 90581985
Infection 41.57 12.21 75 45874 362019 90220479
Exposed bone in jaw 41.53 12.21 23 45926 2903 90579595
Rash 40.75 12.21 237 45712 795863 89786635
Cerebral venous thrombosis 40.64 12.21 21 45928 2307 90580191
Congestive cardiomyopathy 40.53 12.21 32 45917 7322 90575176
Metastases to eye 40.18 12.21 11 45938 198 90582300
Cardiomyopathy 39.53 12.21 50 45899 20156 90562342
Bone cancer metastatic 38.49 12.21 11 45938 233 90582265
Radiation necrosis 38.34 12.21 14 45935 659 90581839
Left ventricular dysfunction 38.16 12.21 42 45907 14627 90567871
Vulvovaginal dryness 38.13 12.21 23 45926 3408 90579090
Metastases to nervous system 38.12 12.21 9 45940 86 90582412
Prescribed overdose 38.11 12.21 3 45946 97622 90484876
Osteosclerosis 38.07 12.21 25 45924 4295 90578203
Metastases to muscle 37.51 12.21 10 45939 162 90582336
Oestrogen receptor assay positive 37.41 12.21 13 45936 529 90581969
Pain in jaw 37.23 12.21 78 45871 47907 90534591
BRAF gene mutation 36.35 12.21 8 45941 54 90582444
Menopause 36.23 12.21 22 45927 3299 90579199
Metastases to uterus 36.03 12.21 9 45940 111 90582387
Onycholysis 35.75 12.21 19 45930 2211 90580287
Vaginal haemorrhage 35.73 12.21 60 45889 31211 90551287
Blood phosphorus increased 35.66 12.21 24 45925 4294 90578204
Endometrial disorder 35.64 12.21 14 45935 807 90581691
Non-compaction cardiomyopathy 35.37 12.21 6 45943 6 90582492
Jaundice 35.32 12.21 61 45888 32456 90550042
Gait inability 35.30 12.21 15 45934 146441 90436057
Central nervous system lesion 35.00 12.21 36 45913 11610 90570888
Radiation skin injury 34.94 12.21 15 45934 1085 90581413
Blood alkaline phosphatase increased 34.83 12.21 76 45873 48003 90534495
Urticaria 34.80 12.21 66 45883 312668 90269830
Confusional state 34.43 12.21 92 45857 386113 90196385
Bursitis 34.19 12.21 12 45937 131642 90450856
Ovarian cyst 34.11 12.21 43 45906 17275 90565223
Endometrial adenocarcinoma 34.02 12.21 16 45933 1434 90581064
Deep vein thrombosis 33.95 12.21 113 45836 91507 90490991
Portal hypertension 33.82 12.21 24 45925 4677 90577821
Uterine haemorrhage 33.58 12.21 24 45925 4728 90577770
Completed suicide 33.18 12.21 16 45933 145042 90437456
Macular hole 33.17 12.21 14 45935 971 90581527
Radiation pneumonitis 33.13 12.21 17 45932 1841 90580657
Pneumonia 33.12 12.21 189 45760 637870 89944628
Blood creatinine decreased 33.04 12.21 27 45922 6488 90576010
Menopausal symptoms 32.58 12.21 20 45929 3058 90579440
Lower respiratory tract infection 32.42 12.21 48 45901 250611 90331887
Myelodysplastic syndrome 32.14 12.21 46 45903 20857 90561641
Reversible cerebral vasoconstriction syndrome 31.84 12.21 22 45927 4108 90578390
Pruritus 31.67 12.21 154 45795 541371 90041127
Depressed mood 31.51 12.21 75 45874 50147 90532351
Postmenopausal haemorrhage 31.51 12.21 18 45931 2412 90580086
Weight increased 31.22 12.21 108 45841 417819 90164679
Protein total decreased 31.05 12.21 27 45922 7062 90575436
Bone sequestrum 30.94 12.21 15 45934 1438 90581060
Intentional product use issue 30.59 12.21 39 45910 216853 90365645
Cerebral haemorrhage 30.22 12.21 59 45890 34463 90548035
Atrophic vulvovaginitis 30.03 12.21 16 45933 1871 90580627
Malignant neoplasm of pleura 30.03 12.21 7 45942 63 90582435
Arteriovenous malformation 29.98 12.21 15 45934 1540 90580958
Gastrointestinal disorder 29.60 12.21 53 45896 256634 90325864
Metastases to stomach 29.46 12.21 9 45940 242 90582256
Adenocarcinoma 29.40 12.21 19 45930 3177 90579321
Road traffic accident 29.37 12.21 9 45940 107617 90474881
Menopausal disorder 29.36 12.21 7 45942 70 90582428
Hepatotoxicity 29.35 12.21 69 45880 45773 90536725
Gingival bleeding 29.34 12.21 37 45912 14866 90567632
Breast disorder 29.34 12.21 18 45931 2749 90579749
Back pain 29.31 12.21 267 45682 316908 90265590
Uterine dilation and curettage 29.28 12.21 13 45936 1020 90581478
Metastases to breast 29.21 12.21 10 45939 389 90582109
Alanine aminotransferase increased 29.04 12.21 128 45821 118210 90464288
Wound infection 28.85 12.21 9 45940 106393 90476105
Neutrophil count increased 28.83 12.21 42 45907 19348 90563150
Meningeal disorder 28.71 12.21 9 45940 264 90582234
Osteitis condensans 28.63 12.21 6 45943 31 90582467
Hepatic steatosis 28.60 12.21 60 45889 36885 90545613
Metastases to abdominal cavity 28.60 12.21 11 45938 599 90581899
Loss of personal independence in daily activities 28.22 12.21 17 45932 136088 90446410
Visual acuity reduced 28.20 12.21 46 45903 23364 90559134
Migraine 28.15 12.21 33 45916 190359 90392139
Jaw disorder 28.11 12.21 23 45926 5536 90576962
Jaw operation 28.07 12.21 12 45937 859 90581639
Adnexa uteri mass 27.98 12.21 11 45938 635 90581863
Ovarian vein thrombosis 27.90 12.21 7 45942 88 90582410
Metastases to soft tissue 27.79 12.21 9 45940 294 90582204
Porphyria non-acute 27.79 12.21 9 45940 294 90582204
Cardiac cirrhosis 27.62 12.21 8 45941 178 90582320
HER2 positive breast cancer 27.61 12.21 10 45939 460 90582038
Pathological fracture 27.48 12.21 29 45920 9631 90572867
Retinal artery occlusion 27.26 12.21 16 45933 2255 90580243
Cervical polyp 27.20 12.21 9 45940 315 90582183
BRCA2 gene mutation 27.14 12.21 7 45942 99 90582399
Leiomyoma 27.02 12.21 10 45939 489 90582009
Tympanic membrane disorder 26.97 12.21 8 45941 194 90582304
Sciatica 26.74 12.21 9 45940 101373 90481125
Hypernatraemia 26.38 12.21 28 45921 9359 90573139
Ovarian failure 26.34 12.21 14 45935 1629 90580869
Blood bilirubin increased 26.29 12.21 64 45885 43406 90539092
Red blood cell sedimentation rate increased 26.26 12.21 5 45944 82590 90499908
Intestinal metastasis 26.19 12.21 8 45941 215 90582283
Hypertransaminasaemia 26.07 12.21 36 45913 15789 90566709
Sequestrectomy 25.86 12.21 11 45938 778 90581720
Neoplasm 25.81 12.21 27 45922 8876 90573622
RET gene mutation 25.77 12.21 5 45944 16 90582482
Alkalosis hypochloraemic 25.48 12.21 8 45941 236 90582262
Adenomyosis 25.36 12.21 10 45939 582 90581916
Joint range of motion decreased 25.36 12.21 19 45930 135624 90446874
Tumour flare 25.30 12.21 10 45939 586 90581912
Cardiotoxicity 25.21 12.21 30 45919 11359 90571139
Therapeutic product effect incomplete 25.19 12.21 37 45912 193859 90388639
Actinomycosis 25.02 12.21 12 45937 1124 90581374
Endometrial cancer stage I 24.92 12.21 8 45941 254 90582244
Chronic myeloid leukaemia 24.91 12.21 16 45933 2648 90579850
Tumour marker decreased 24.73 12.21 6 45943 65 90582433
Ventricular hypokinesia 24.73 12.21 21 45928 5320 90577178
Central nervous system infection 24.69 12.21 11 45938 870 90581628
Toothache 24.53 12.21 42 45907 22188 90560310
Cardiac failure 24.31 12.21 115 45834 109381 90473117
Ill-defined disorder 24.30 12.21 35 45914 184856 90397642
Drug abuse 24.13 12.21 6 45943 82341 90500157
Neoplasm malignant 23.91 12.21 53 45896 33827 90548671
Sensory disturbance 23.82 12.21 34 45915 15379 90567119
Injection site extravasation 23.77 12.21 26 45923 8993 90573505
Liver injury 23.71 12.21 31 45918 170536 90411962
Neutrophil count decreased 23.69 12.21 85 45864 71447 90511051
Alopecia areata 23.67 12.21 14 45935 2001 90580497
Osteomyelitis 23.66 12.21 47 45902 27799 90554699
Tumour invasion 23.65 12.21 8 45941 300 90582198
Musculoskeletal stiffness 23.25 12.21 75 45874 296457 90286041
Medication error 23.24 12.21 7 45942 84645 90497853
Abdominal lymphadenopathy 23.20 12.21 11 45938 1004 90581494
Mastectomy 23.14 12.21 14 45935 2085 90580413
Heart rate irregular 23.12 12.21 43 45906 24225 90558273
Myalgia 23.07 12.21 160 45789 174965 90407533
Peripheral venous disease 22.93 12.21 7 45942 83914 90498584
Haemangioma of liver 22.89 12.21 12 45937 1358 90581140
Alopecia 22.87 12.21 152 45797 494919 90087579
Breast cancer in situ 22.86 12.21 13 45936 1727 90580771
Product administered at inappropriate site 22.74 12.21 18 45931 4133 90578365
Gastrointestinal toxicity 22.73 12.21 26 45923 9441 90573057
Malignant neoplasm of choroid 22.69 12.21 4 45945 6 90582492
Neuroendocrine breast tumour 22.56 12.21 5 45944 35 90582463
Hepatic neoplasm 22.55 12.21 14 45935 2184 90580314
Pneumonitis 22.54 12.21 61 45888 44109 90538389
Mucosal dryness 22.39 12.21 16 45933 3151 90579347
Upper respiratory fungal infection 22.38 12.21 7 45942 204 90582294
Ovarian cancer metastatic 22.35 12.21 11 45938 1090 90581408
Oestradiol increased 22.35 12.21 6 45943 100 90582398
Performance status decreased 22.25 12.21 18 45931 4262 90578236
Neurotoxicity 21.67 12.21 39 45910 21428 90561070
Skin hypopigmentation 21.64 12.21 11 45938 1168 90581330
Hysterectomy 21.61 12.21 28 45921 11556 90570942
Meningioma 21.58 12.21 19 45930 5052 90577446
Acute lymphocytic leukaemia 21.56 12.21 15 45934 2833 90579665
Metastases to bone marrow 21.52 12.21 9 45940 610 90581888
Fibrous histiocytoma 21.51 12.21 9 45940 611 90581887
Hip arthroplasty 21.48 12.21 6 45943 76202 90506296
Neutrophilia 21.35 12.21 20 45929 5758 90576740
Deprescribing error 21.35 12.21 5 45944 46 90582452
Chronic myelomonocytic leukaemia 21.30 12.21 8 45941 408 90582090
Injection site reaction 21.29 12.21 10 45939 92070 90490428
Disturbance in attention 21.04 12.21 62 45887 47047 90535451
Glioblastoma multiforme 20.94 12.21 10 45939 928 90581570
Libido decreased 20.93 12.21 15 45934 2967 90579531
Dental operation 20.89 12.21 12 45937 1624 90580874
Knee arthroplasty 20.89 12.21 8 45941 83174 90499324
Bone cancer 20.72 12.21 12 45937 1650 90580848
Ear infection 20.60 12.21 5 45944 69770 90512728
Intentional overdose 20.48 12.21 11 45938 93823 90488675
Skin toxicity 20.45 12.21 21 45928 6758 90575740
Madarosis 20.45 12.21 16 45933 3613 90578885
Spinal pain 20.39 12.21 32 45917 15735 90566763
Ovarian cancer stage IV 20.21 12.21 7 45942 282 90582216
Oophorectomy 20.13 12.21 9 45940 718 90581780
Intermenstrual bleeding 19.93 12.21 24 45925 9199 90573299
Neuromuscular toxicity 19.93 12.21 7 45942 294 90582204
Aspartate aminotransferase increased 19.93 12.21 104 45845 102833 90479665
Memory impairment 19.91 12.21 44 45905 197200 90385298
Uterine polypectomy 19.76 12.21 3 45946 0 90582498
Pain 19.53 12.21 372 45577 995969 89586529
Breath odour 19.49 12.21 11 45938 1440 90581058
Psoriasis 19.38 12.21 28 45921 147726 90434772
Product quality issue 19.31 12.21 8 45941 79317 90503181
Hypophosphatasia 19.24 12.21 5 45944 73 90582425
Impaired healing 19.22 12.21 58 45891 234141 90348357
Breast neoplasm 18.62 12.21 11 45938 1569 90580929
Drug resistance 18.59 12.21 45 45904 30404 90552094
Anaemia 18.51 12.21 266 45683 352536 90229962
Oedema 18.37 12.21 47 45902 200248 90382250
Debridement 18.23 12.21 10 45939 1239 90581259
Respiratory tract inflammation 18.21 12.21 8 45941 612 90581886
Skin fragility 18.12 12.21 9 45940 909 90581589
Diabetic hyperosmolar coma 18.06 12.21 7 45942 389 90582109
Portal vein thrombosis 18.04 12.21 14 45935 3124 90579374
Mucosal toxicity 17.96 12.21 7 45942 395 90582103
Osteoarthritis 17.90 12.21 46 45903 195684 90386814
Skeletal injury 17.86 12.21 10 45939 1289 90581209
Hypercholesterolaemia 17.77 12.21 15 45934 100877 90481621
Adverse event 17.73 12.21 20 45929 117398 90465100
Pulmonary fibrosis 17.71 12.21 17 45932 107486 90475012
Oxygen saturation decreased 17.71 12.21 17 45932 107466 90475032
Glomerular filtration rate abnormal 17.54 12.21 10 45939 1335 90581163
Periodontitis 17.53 12.21 15 45934 3838 90578660
Electrocardiogram QT prolonged 17.49 12.21 78 45871 72378 90510120
Night sweats 17.29 12.21 24 45925 128742 90453756
Desmoid tumour 17.23 12.21 5 45944 112 90582386
Hydronephrosis 17.20 12.21 26 45923 12376 90570122
Arthritis 17.16 12.21 37 45912 167278 90415220
Respiratory tract oedema 17.04 12.21 8 45941 714 90581784
Obesity 17.02 12.21 17 45932 105490 90477008
Polypectomy 16.98 12.21 9 45940 1041 90581457
Carcinoembryonic antigen increased 16.91 12.21 12 45937 2338 90580160
Non-alcoholic steatohepatitis 16.85 12.21 11 45938 1871 90580627
Soft tissue infection 16.82 12.21 13 45936 2884 90579614
Gastrointestinal bacterial infection 16.74 12.21 9 45940 1071 90581427
Diarrhoea 16.71 12.21 607 45342 938583 89643915
Musculoskeletal chest pain 16.58 12.21 37 45912 23713 90558785
Oesophageal varices haemorrhage 16.57 12.21 10 45939 1482 90581016
Blood lactate dehydrogenase increased 16.56 12.21 39 45910 25893 90556605
Lymphangioleiomyomatosis 16.52 12.21 6 45943 278 90582220
Gingivitis 16.48 12.21 22 45927 9347 90573151
Skin atrophy 16.45 12.21 17 45932 5512 90576986
Blood bilirubin abnormal 16.42 12.21 11 45938 1953 90580545
Product dose omission issue 16.42 12.21 84 45865 291603 90290895
Cortisol increased 16.40 12.21 7 45942 499 90581999
Dyspepsia 16.31 12.21 49 45900 198111 90384387
Enterocolitis bacterial 16.24 12.21 6 45943 292 90582206
Intentional product misuse 16.18 12.21 13 45936 89591 90492907
Cerebral haematoma 16.15 12.21 15 45934 4274 90578224
Breast reconstruction 16.14 12.21 6 45943 297 90582201
Breast pain 16.12 12.21 23 45926 10395 90572103
Nail disorder 16.12 12.21 66 45883 59001 90523497
Anaplastic thyroid cancer 16.12 12.21 4 45945 48 90582450
Gamma-glutamyltransferase increased 16.05 12.21 49 45900 37903 90544595
Breast cancer stage IV 16.05 12.21 11 45938 2027 90580471
Liver scan abnormal 16.04 12.21 4 45945 49 90582449
Atypical femur fracture 16.04 12.21 18 45931 6403 90576095
Fungal disease carrier 15.75 12.21 4 45945 53 90582445
Hepatic cyst 15.71 12.21 18 45931 6550 90575948
Salpingitis 15.56 12.21 6 45943 329 90582169
Haemorrhage 15.50 12.21 73 45876 69296 90513202
Septic shock 15.46 12.21 12 45937 84148 90498350
Oral pustule 15.42 12.21 4 45945 58 90582440
Hospitalisation 15.16 12.21 26 45923 128074 90454424
Bile duct stenosis 15.15 12.21 10 45939 1732 90580766
Atypical fracture 15.11 12.21 8 45941 923 90581575
Coagulation factor V level decreased 15.11 12.21 6 45943 356 90582142
Frequent bowel movements 15.11 12.21 5 45944 56930 90525568
Atrial thrombosis 15.09 12.21 11 45938 2234 90580264
Aeromonas infection 15.08 12.21 5 45944 176 90582322
Hydrocephalus 15.08 12.21 17 45932 6077 90576421
Invasive breast carcinoma 15.05 12.21 8 45941 931 90581567
Hair texture abnormal 15.02 12.21 15 45934 4672 90577826
Therapy partial responder 15.01 12.21 34 45915 22009 90560489
Corneal degeneration 14.97 12.21 5 45944 180 90582318
Purulent discharge 14.97 12.21 16 45933 5389 90577109
Injection site bruising 14.96 12.21 4 45945 52303 90530195
Tooth disorder 14.93 12.21 42 45907 31048 90551450
Intraductal proliferative breast lesion 14.82 12.21 13 45936 3440 90579058
Dry mouth 14.80 12.21 46 45903 184013 90398485
Amnesia 14.79 12.21 20 45929 108485 90474013
Blood copper increased 14.75 12.21 3 45946 13 90582485
Product use in unapproved indication 14.64 12.21 105 45844 336131 90246367
Chronic hepatic failure 14.63 12.21 7 45942 652 90581846
Blood follicle stimulating hormone increased 14.62 12.21 5 45944 194 90582304
Paraneoplastic syndrome 14.58 12.21 7 45942 657 90581841
Dental caries 14.55 12.21 23 45926 11374 90571124
Nasal dryness 14.55 12.21 16 45933 5567 90576931
Deafness 14.53 12.21 34 45915 22480 90560018
Overdose 14.47 12.21 37 45912 157672 90424826
Back injury 14.45 12.21 3 45946 46619 90535879
Pelvic mass 14.45 12.21 9 45940 1412 90581086
Corneal graft rejection 14.41 12.21 4 45945 76 90582422
Pulmonary radiation injury 14.40 12.21 3 45946 15 90582483
Encephalopathy 14.37 12.21 3 45946 46441 90536057
Pelvic pain 14.37 12.21 27 45922 15330 90567168
Uterine mass 14.31 12.21 6 45943 409 90582089
Somnolence 14.30 12.21 56 45893 209028 90373470
Menstruation irregular 14.29 12.21 19 45930 8041 90574457
Blood follicle stimulating hormone decreased 14.23 12.21 3 45946 16 90582482
Platelet count abnormal 14.12 12.21 14 45935 4321 90578177
Gastrointestinal haemorrhage 14.04 12.21 15 45934 90233 90492265
Erysipelas 14.03 12.21 20 45929 9032 90573466
Activated PI3 kinase delta syndrome 14.03 12.21 4 45945 84 90582414
Salpingo-oophorectomy bilateral 13.98 12.21 6 45943 434 90582064
Ventricular dysfunction 13.95 12.21 13 45936 3718 90578780
Metastases to meninges 13.94 12.21 13 45936 3722 90578776
Metastases to neck 13.85 12.21 4 45945 88 90582410
Hepatic cancer metastatic 13.83 12.21 6 45943 445 90582053
Retinal vein occlusion 13.82 12.21 11 45938 2545 90579953
Diverticulitis 13.82 12.21 3 45946 45184 90537314
Varices oesophageal 13.81 12.21 13 45936 3766 90578732
Neuroendocrine carcinoma metastatic 13.80 12.21 5 45944 230 90582268
Renal neoplasm 13.80 12.21 9 45940 1528 90580970
Trigger finger 13.79 12.21 15 45934 5155 90577343
Metastatic lymphoma 13.78 12.21 5 45944 231 90582267
Anorectal disorder 13.76 12.21 10 45939 2021 90580477
Corneal disorder 13.72 12.21 10 45939 2032 90580466
Marrow hyperplasia 13.69 12.21 7 45942 752 90581746
Cutaneous sarcoidosis 13.66 12.21 6 45943 459 90582039
Vertebral lesion 13.58 12.21 7 45942 765 90581733
Sensory loss 13.58 12.21 29 45920 18046 90564452
Product monitoring error 13.57 12.21 14 45935 4530 90577968
Papillary thyroid cancer 13.56 12.21 11 45938 2616 90579882
Joint dislocation 13.55 12.21 3 45946 44579 90537919
Benign lymph node neoplasm 13.54 12.21 3 45946 21 90582477
Eosinophil count increased 13.50 12.21 24 45925 13057 90569441
Bone erosion 13.48 12.21 5 45944 53016 90529482
Scapula fracture 13.45 12.21 6 45943 476 90582022
Skin exfoliation 13.41 12.21 69 45880 67844 90514654
Subclavian vein thrombosis 13.40 12.21 10 45939 2106 90580392
Superior sagittal sinus thrombosis 13.30 12.21 7 45942 799 90581699
Pericardial effusion 13.26 12.21 45 45904 36788 90545710
Leukopenia 13.25 12.21 92 45857 100618 90481880
Asthenia 13.16 12.21 359 45590 533392 90049106
Internal fixation of fracture 13.15 12.21 7 45942 817 90581681
Osteopenia 12.99 12.21 33 45916 22969 90559529
Femur fracture 12.98 12.21 52 45897 46030 90536468
Rapidly progressive osteoarthritis 12.97 12.21 3 45946 26 90582472
Cellulitis 12.95 12.21 85 45864 91252 90491246
Periodontal disease 12.92 12.21 9 45940 1703 90580795
Brain abscess 12.90 12.21 11 45938 2801 90579697
C-reactive protein increased 12.78 12.21 48 45901 181341 90401157
Blood luteinising hormone decreased 12.77 12.21 3 45946 28 90582470
Cholestasis 12.76 12.21 44 45905 36255 90546243
Hair colour changes 12.73 12.21 12 45937 3482 90579016
Ischaemic stroke 12.73 12.21 32 45917 22134 90560364
Axillary lymphadenectomy 12.71 12.21 4 45945 119 90582379
Hormone receptor positive HER2 negative breast cancer 12.55 12.21 5 45944 299 90582199
Ovarian granulosa-theca cell tumour 12.50 12.21 3 45946 31 90582467
Paraparesis 12.48 12.21 11 45938 2927 90579571
Blood phosphorus decreased 12.38 12.21 14 45935 5020 90577478
Asthma 12.38 12.21 72 45877 242088 90340410
Stomatitis 12.33 12.21 85 45864 274613 90307885
Adenoid cystic carcinoma 12.33 12.21 3 45946 33 90582465
Blood potassium abnormal 12.31 12.21 11 45938 2983 90579515
HER2 gene amplification 12.24 12.21 3 45946 34 90582464

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 86.67 24.45 29 1561 14780 42604965
Carbohydrate antigen 15-3 increased 63.36 24.45 9 1581 69 42619676
Metastases to lung 57.52 24.45 20 1570 11404 42608341
Breast cancer metastatic 38.43 24.45 6 1584 92 42619653
PIK3CA-activated mutation 36.74 24.45 6 1584 124 42619621
Metastases to central nervous system 33.15 24.45 13 1577 10342 42609403
Malignant neoplasm progression 32.37 24.45 29 1561 108371 42511374
Metastases to the mediastinum 30.72 24.45 6 1584 349 42619396
Cardiac ventricular thrombosis 30.23 24.45 8 1582 1814 42617931
Encapsulating peritoneal sclerosis 27.46 24.45 6 1584 606 42619139
Hepatic lesion 27.04 24.45 9 1581 4485 42615260
Hot flush 26.38 24.45 14 1576 22337 42597408
Breast cancer 25.13 24.45 5 1585 320 42619425
Mass 24.59 24.45 10 1580 8729 42611016

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 1644.66 12.82 551 36528 30821 110521399
Malignant neoplasm progression 1076.28 12.82 690 36389 173877 110378343
Metastases to liver 764.03 12.82 325 36754 35061 110517159
Metastases to lung 627.53 12.82 250 36829 22813 110529407
Breast cancer recurrent 546.06 12.82 146 36933 3700 110548520
Breast cancer metastatic 486.38 12.82 171 36908 11010 110541210
Metastases to lymph nodes 437.06 12.82 171 36908 14861 110537359
Disease progression 350.37 12.82 420 36659 243614 110308606
Neoplasm progression 321.54 12.82 224 36855 64371 110487849
Breast cancer 302.15 12.82 178 36901 38364 110513856
Osteonecrosis of jaw 244.75 12.82 169 36910 47848 110504372
Metastases to central nervous system 199.07 12.82 113 36966 22704 110529516
Metastases to spine 188.44 12.82 70 37009 5273 110546947
Endometrial cancer 164.01 12.82 52 37027 2424 110549796
Hot flush 163.19 12.82 152 36927 65884 110486336
Bone lesion 149.21 12.82 64 37015 7023 110545197
Metastasis 139.74 12.82 64 37015 8203 110544017
Second primary malignancy 127.44 12.82 78 37001 17990 110534230
Neuropathy peripheral 127.20 12.82 221 36858 179056 110373164
Metastases to skin 126.71 12.82 42 37037 2257 110549963
Tumour marker increased 120.90 12.82 50 37029 5010 110547210
Acute myeloid leukaemia 116.57 12.82 99 36980 38011 110514209
Sarcoma uterus 116.24 12.82 18 37061 13 110552207
Endometrial hyperplasia 115.68 12.82 30 37049 672 110551548
Metastases to pleura 110.95 12.82 37 37042 2026 110550194
Metastases to the mediastinum 107.35 12.82 29 37050 764 110551456
Hepatic lesion 104.84 12.82 53 37026 8440 110543780
Osteonecrosis 103.92 12.82 88 36991 33653 110518567
Bone pain 103.03 12.82 118 36961 65015 110487205
PIK3CA-activated mutation 102.42 12.82 27 37052 646 110551574
Carbohydrate antigen 15-3 increased 99.64 12.82 32 37047 1555 110550665
Neutropenia 95.22 12.82 309 36770 374311 110177909
Lymphoedema 94.08 12.82 60 37019 14869 110537351
Maculopathy 93.51 12.82 36 37043 2991 110549229
Bone disorder 90.49 12.82 67 37012 21125 110531095
Pseudocirrhosis 89.52 12.82 26 37053 897 110551323
Device related thrombosis 85.40 12.82 35 37044 3427 110548793
Breast mass 83.87 12.82 45 37034 8096 110544124
Tonsillar disorder 81.25 12.82 27 37052 1462 110550758
Uterine polyp 81.16 12.82 29 37050 1954 110550266
Lymphadenopathy 78.76 12.82 102 36977 63733 110488487
Metastases to pelvis 78.23 12.82 23 37056 829 110551391
Endometrial atrophy 73.51 12.82 13 37066 37 110552183
Ejection fraction decreased 73.14 12.82 79 37000 40801 110511419
Metastases to chest wall 69.83 12.82 20 37059 656 110551564
Osteolysis 69.74 12.82 35 37044 5488 110546732
Synovitis 69.63 12.82 6 37073 274086 110278134
Haematotoxicity 69.08 12.82 57 37022 21025 110531195
Recurrent cancer 69.06 12.82 30 37049 3393 110548827
Hormone receptor positive breast cancer 68.35 12.82 19 37060 558 110551662
Uterine cancer 66.45 12.82 31 37048 4143 110548077
Systemic lupus erythematosus 66.18 12.82 5 37074 254333 110297887
Nasal disorder 66.02 12.82 31 37048 4203 110548017
Pulmonary mass 64.84 12.82 71 37008 37230 110514990
Metastases to eye 63.32 12.82 16 37063 322 110551898
Glossodynia 61.87 12.82 3 37076 222001 110330219
Retinopathy 61.67 12.82 30 37049 4399 110547821
Joint swelling 61.64 12.82 36 37043 442809 110109411
Palmar-plantar erythrodysaesthesia syndrome 59.33 12.82 71 37008 40954 110511266
Invasive ductal breast carcinoma 58.19 12.82 33 37046 6613 110545607
Blood uric acid decreased 57.97 12.82 21 37058 1472 110550748
Therapeutic product effect decreased 57.77 12.82 7 37072 244309 110307911
Metastases to peritoneum 57.76 12.82 31 37048 5579 110546641
Invasive lobular breast carcinoma 57.25 12.82 18 37061 816 110551404
Wound 57.24 12.82 6 37073 234431 110317789
Excessive eye blinking 56.91 12.82 22 37057 1848 110550372
Breast cancer female 56.81 12.82 41 37038 12427 110539793
Eosinophil percentage increased 56.79 12.82 21 37058 1561 110550659
Acute promyelocytic leukaemia 56.61 12.82 22 37057 1874 110550346
Amenorrhoea 55.44 12.82 36 37043 9195 110543025
Pseudocellulitis 54.31 12.82 15 37064 430 110551790
Disease recurrence 53.99 12.82 83 36996 60701 110491519
Hypertriglyceridaemia 51.52 12.82 43 37036 16111 110536109
Uterine leiomyoma 50.77 12.82 32 37047 7768 110544452
Eastern Cooperative Oncology Group performance status worsened 50.22 12.82 23 37056 2946 110549274
Contraindicated product administered 50.05 12.82 11 37068 248256 110303964
Pulmonary embolism 48.31 12.82 170 36909 214304 110337916
Recall phenomenon 48.16 12.82 18 37061 1378 110550842
Endometrial thickening 48.09 12.82 14 37065 487 110551733
Lymphadenopathy mediastinal 47.39 12.82 27 37052 5457 110546763
Rheumatoid arthritis 46.67 12.82 21 37058 299592 110252628
Endometrial hypertrophy 46.20 12.82 11 37068 171 110552049
Vitreous detachment 46.20 12.82 21 37058 2644 110549576
Congestive cardiomyopathy 45.66 12.82 38 37041 14181 110538039
Bronchomalacia 44.86 12.82 12 37067 304 110551916
Hepatic enzyme increased 44.75 12.82 26 37053 320866 110231354
Folliculitis 44.46 12.82 3 37076 167650 110384570
Lymphangiosis carcinomatosa 44.43 12.82 20 37059 2462 110549758
Left ventricular dilatation 44.24 12.82 17 37062 1405 110550815
Mucosal toxicity 43.36 12.82 14 37065 692 110551528
Completed suicide 42.71 12.82 14 37065 242367 110309853
Cerebral venous thrombosis 42.15 12.82 21 37058 3241 110548979
Endometriosis 41.98 12.82 23 37056 4311 110547909
Ovarian cancer 41.67 12.82 23 37056 4373 110547847
Pleural disorder 41.51 12.82 15 37064 1044 110551176
Peritoneal disorder 41.20 12.82 14 37065 812 110551408
Psoriatic arthropathy 41.14 12.82 8 37071 196753 110355467
Menopausal symptoms 41.13 12.82 19 37060 2482 110549738
Oestradiol abnormal 40.90 12.82 8 37071 45 110552175
Cardiomyopathy 40.46 12.82 53 37026 33472 110518748
BRCA2 gene mutation 40.04 12.82 9 37070 107 110552113
Reversible cerebral vasoconstriction syndrome 39.96 12.82 23 37056 4738 110547482
Postmenopausal haemorrhage 39.94 12.82 17 37062 1829 110550391
Endometrial adenocarcinoma 38.94 12.82 15 37064 1248 110550972
Pleural effusion 38.42 12.82 139 36940 177570 110374650
Infusion related reaction 38.06 12.82 43 37036 381119 110171101
Left ventricular dysfunction 37.88 12.82 43 37036 23450 110528770
Metastases to ovary 37.61 12.82 11 37068 389 110551831
Radiation necrosis 36.89 12.82 13 37066 841 110551379
Pericarditis 36.31 12.82 14 37065 219100 110333120
Pathological fracture 36.26 12.82 31 37048 12001 110540219
Hepatotoxicity 35.92 12.82 71 37008 63329 110488891
Ascites 35.69 12.82 89 36990 92719 110459501
Vaginal haemorrhage 35.61 12.82 43 37036 25031 110527189
Adnexa uteri mass 35.54 12.82 11 37068 473 110551747
Menopausal disorder 35.54 12.82 7 37072 41 110552179
Pneumonia 35.07 12.82 163 36916 876551 109675669
Menopause 34.76 12.82 17 37062 2521 110549699
Depressed mood 34.33 12.82 68 37011 60741 110491479
Hypersensitivity 33.76 12.82 52 37027 403946 110148274
Wheezing 33.75 12.82 22 37057 255208 110297012
Fibromyalgia 33.59 12.82 8 37071 170901 110381319
Injury 33.48 12.82 9 37070 177256 110374964
Metastatic neoplasm 33.07 12.82 22 37057 5851 110546369
Radiation pneumonitis 33.06 12.82 20 37059 4516 110547704
Arteriovenous malformation 32.64 12.82 15 37064 1936 110550284
Breast cancer in situ 32.57 12.82 13 37066 1188 110551032
Ovarian hyperstimulation syndrome 32.43 12.82 21 37058 5339 110546881
Ovarian cyst 32.35 12.82 31 37048 13899 110538321
Uterine haemorrhage 32.35 12.82 18 37061 3476 110548744
Malignant pleural effusion 32.31 12.82 19 37060 4074 110548146
Metastases to thorax 31.85 12.82 9 37070 281 110551939
Ovarian vein thrombosis 31.56 12.82 7 37072 78 110552142
Arthropathy 31.44 12.82 30 37049 287492 110264728
Metastases to uterus 31.39 12.82 7 37072 80 110552140
Osteitis condensans 31.10 12.82 6 37073 31 110552189
Exposed bone in jaw 30.90 12.82 18 37061 3793 110548427
Osteosclerosis 30.58 12.82 19 37060 4496 110547724
Blood creatinine decreased 30.55 12.82 25 37054 9112 110543108
Tooth extraction 30.34 12.82 29 37050 12962 110539258
Tympanic membrane disorder 30.20 12.82 8 37071 195 110552025
Acute kidney injury 29.82 12.82 111 36968 635319 109916901
Adenomyosis 29.59 12.82 9 37070 365 110551855
Hepatic steatosis 29.26 12.82 56 37023 48775 110503445
Skin toxicity 28.85 12.82 27 37052 11756 110540464
Radiation skin injury 28.73 12.82 13 37066 1619 110550601
Hydrothorax 28.54 12.82 13 37066 1645 110550575
Tumour marker decreased 28.21 12.82 6 37073 54 110552166
Deep vein thrombosis 28.20 12.82 107 36972 139780 110412440
Alopecia areata 28.03 12.82 14 37065 2173 110550047
Bursitis 27.76 12.82 5 37074 129913 110422307
Back pain 27.71 12.82 216 36863 370780 110181440
Sepsis 27.47 12.82 42 37037 327304 110224916
Maternal exposure during pregnancy 27.40 12.82 27 37052 254856 110297364
Cardiotoxicity 27.39 12.82 31 37048 16850 110535370
Cardiac cirrhosis 27.38 12.82 8 37071 282 110551938
Atrophic vulvovaginitis 27.37 12.82 12 37067 1388 110550832
Exposure during pregnancy 27.23 12.82 11 37068 167413 110384807
Blood cholesterol increased 27.16 12.82 14 37065 184771 110367449
Swelling 26.71 12.82 48 37031 350993 110201227
Type 2 diabetes mellitus 26.70 12.82 13 37066 177219 110375001
Abdominal discomfort 26.41 12.82 58 37021 393800 110158420
Condition aggravated 26.28 12.82 142 36937 734694 109817526
Sequestrectomy 26.03 12.82 10 37069 826 110551394
Endometrial cancer stage I 25.85 12.82 7 37072 186 110552034
Hysteroscopy 25.73 12.82 5 37074 27 110552193
Hypertransaminasaemia 25.70 12.82 36 37043 24219 110528001
Mobility decreased 25.69 12.82 25 37054 237397 110314823
Neoplasm recurrence 25.67 12.82 18 37061 5214 110547006
Portal hypertension 25.51 12.82 22 37057 8615 110543605
Product administered at inappropriate site 25.18 12.82 18 37061 5375 110546845
Spinal pain 25.07 12.82 31 37048 18484 110533736
Protein total decreased 24.85 12.82 24 37055 10866 110541354
Treatment failure 24.81 12.82 34 37045 277200 110275020
Neuroendocrine breast tumour 24.62 12.82 5 37074 35 110552185
Septic shock 24.58 12.82 11 37068 157517 110394703
Ovarian failure 24.53 12.82 10 37069 966 110551254
Breast disorder 24.42 12.82 13 37066 2301 110549919
Disturbance in attention 24.41 12.82 60 37019 61935 110490285
Injection site extravasation 24.32 12.82 23 37056 10146 110542074
Mucosal inflammation 24.08 12.82 79 37000 96062 110456158
Macular hole 24.00 12.82 10 37069 1021 110551199
Spinal cord compression 23.87 12.82 20 37059 7532 110544688
Gastrointestinal haemorrhage 23.65 12.82 13 37066 165505 110386715
Porphyria non-acute 23.37 12.82 9 37070 748 110551472
Blood alkaline phosphatase increased 23.16 12.82 64 37015 70871 110481349
Pain in jaw 22.83 12.82 52 37027 51125 110501095
Metastases to stomach 22.49 12.82 7 37072 307 110551913
Fibrous histiocytoma 22.47 12.82 9 37070 830 110551390
Deprescribing error 22.36 12.82 5 37074 58 110552162
Vulvovaginal dryness 22.34 12.82 13 37066 2734 110549486
Non-compaction cardiomyopathy 22.28 12.82 5 37074 59 110552161
Metastases to abdominal cavity 22.08 12.82 9 37070 869 110551351
RET gene mutation 21.99 12.82 4 37075 14 110552206
Central nervous system infection 21.94 12.82 11 37068 1721 110550499
Gingival bleeding 21.85 12.82 30 37049 19809 110532411
Retinal artery occlusion 21.74 12.82 15 37064 4234 110547986
Mucosal dryness 21.70 12.82 15 37064 4248 110547972
Chronic myeloid leukaemia 21.66 12.82 15 37064 4258 110547962
Discomfort 21.66 12.82 24 37055 214683 110337537
Alkalosis hypochloraemic 21.65 12.82 8 37071 593 110551627
Drug hypersensitivity 21.49 12.82 79 37000 454011 110098209
Fatigue 21.44 12.82 546 36533 1215412 109336808
Metastases to meninges 21.41 12.82 16 37063 5112 110547108
Infection 21.38 12.82 57 37022 362143 110190077
Abdominal lymphadenopathy 21.38 12.82 11 37068 1817 110550403
Metastases to breast 21.26 12.82 7 37072 368 110551852
Intermenstrual bleeding 21.17 12.82 18 37061 6916 110545304
Central nervous system lesion 20.99 12.82 26 37053 15527 110536693
Vertebral lesion 20.81 12.82 8 37071 662 110551558
Atypical femur fracture 20.76 12.82 17 37062 6202 110546018
Gastrointestinal toxicity 20.74 12.82 22 37057 11126 110541094
Toothache 20.66 12.82 32 37047 23543 110528677
Non-alcoholic steatohepatitis 20.66 12.82 12 37067 2515 110549705
Hepatic neoplasm 20.61 12.82 14 37065 3853 110548367
Pelvic pain 20.48 12.82 26 37053 15916 110536304
Leiomyoma 20.42 12.82 7 37072 417 110551803
Alanine aminotransferase increased 20.33 12.82 118 36961 183655 110368565
Metastases to soft tissue 20.26 12.82 8 37071 711 110551509
Blister 20.22 12.82 28 37051 227348 110324872
Pneumonitis 20.17 12.82 64 37015 76467 110475753
Heart rate irregular 20.16 12.82 39 37040 34235 110517985
Oxygen saturation decreased 20.11 12.82 14 37065 156968 110395252
Lymphangioleiomyomatosis 20.08 12.82 6 37073 229 110551991
Meningioma 20.00 12.82 16 37063 5649 110546571
Nausea 19.81 12.82 548 36531 1235142 109317078
Hormone receptor positive HER2 negative breast cancer 19.81 12.82 6 37073 240 110551980
Urticaria 19.73 12.82 49 37030 318808 110233412
Superior sagittal sinus thrombosis 19.72 12.82 9 37070 1144 110551076
Hypernatraemia 19.69 12.82 27 37052 17806 110534414
Meningeal disorder 19.69 12.82 7 37072 465 110551755
Skin fragility 19.68 12.82 9 37070 1149 110551071
Nail disorder 19.64 12.82 53 37026 57882 110494338
Cerebral haemorrhage 19.63 12.82 57 37022 64911 110487309
Madarosis 19.57 12.82 13 37066 3450 110548770
Polyneuropathy 19.53 12.82 37 37042 31975 110520245
Prescribed overdose 19.53 12.82 3 37076 87578 110464642
Invasive breast carcinoma 19.48 12.82 8 37071 787 110551433
Visual acuity reduced 19.40 12.82 37 37042 32136 110520084
Subclavian vein thrombosis 19.39 12.82 12 37067 2820 110549400
Cervical polyp 19.34 12.82 6 37073 260 110551960
Road traffic accident 19.27 12.82 6 37073 107392 110444828
Bone sequestrum 19.14 12.82 9 37070 1224 110550996
Nasopharyngitis 19.06 12.82 68 37011 394293 110157927
Metabolic acidosis 18.95 12.82 5 37074 99739 110452481
Pruritus 18.83 12.82 116 36963 581444 109970776
Sinusitis 18.82 12.82 45 37034 296643 110255577
Confusional state 18.77 12.82 87 36992 468593 110083627
Encapsulating peritoneal sclerosis 18.63 12.82 8 37071 880 110551340
Sensory loss 18.63 12.82 29 37050 21428 110530792
Hypophosphatasia 18.61 12.82 5 37074 129 110552091
Neutrophilia 18.54 12.82 20 37059 10309 110541911
Performance status decreased 18.47 12.82 17 37062 7249 110544971
Loss of personal independence in daily activities 18.41 12.82 14 37065 150006 110402214
Breast reconstruction 18.39 12.82 5 37074 135 110552085
Tumour invasion 18.27 12.82 7 37072 574 110551646
Gastrointestinal bacterial infection 17.94 12.82 9 37070 1409 110550811
Uterine mass 17.86 12.82 6 37073 336 110551884
Nasal dryness 17.81 12.82 15 37064 5691 110546529
Myocardial infarction 17.74 12.82 23 37056 192060 110360160
Gait inability 17.69 12.82 12 37067 136364 110415856
Cortisol increased 17.67 12.82 7 37072 627 110551593
Menstruation irregular 17.60 12.82 15 37064 5782 110546438
Mastectomy 17.40 12.82 9 37070 1502 110550718
Respiratory tract inflammation 17.39 12.82 8 37071 1035 110551185
Anaplastic thyroid cancer 17.33 12.82 4 37075 54 110552166
Breast pain 17.31 12.82 19 37060 9981 110542239
Libido decreased 17.29 12.82 15 37064 5920 110546300
Breast neoplasm 17.28 12.82 8 37071 1050 110551170
Ventricular hypokinesia 17.19 12.82 20 37059 11194 110541026
Sensory disturbance 17.19 12.82 25 37054 17404 110534816
Soft tissue infection 17.13 12.82 14 37065 5093 110547127
HER2 positive breast cancer 17.04 12.82 6 37073 387 110551833
Onycholysis 17.02 12.82 11 37068 2788 110549432
Cystoid macular oedema 17.01 12.82 11 37068 2789 110549431
Haemorrhagic cyst 16.85 12.82 6 37073 400 110551820
Respiratory tract oedema 16.83 12.82 8 37071 1115 110551105
Joint range of motion decreased 16.79 12.82 10 37069 121822 110430398
Intentional overdose 16.73 12.82 12 37067 132489 110419731
Neuromuscular toxicity 16.64 12.82 6 37073 415 110551805
Dyspareunia 16.60 12.82 10 37069 2239 110549981
Upper respiratory fungal infection 16.56 12.82 6 37073 421 110551799
Deafness 16.46 12.82 31 37048 26678 110525542
Multiple organ dysfunction syndrome 16.38 12.82 16 37063 151694 110400526
Liver scan abnormal 16.36 12.82 4 37075 70 110552150
Product use issue 16.25 12.82 52 37027 311643 110240577
Wound infection 16.25 12.82 6 37073 96459 110455761
Ovarian cancer metastatic 16.18 12.82 7 37072 784 110551436
Hair colour changes 16.01 12.82 13 37066 4688 110547532
Gastrointestinal disorder 15.90 12.82 36 37043 241916 110310304
Cardiac ventricular thrombosis 15.84 12.82 11 37068 3136 110549084
Therapy partial responder 15.81 12.82 37 37042 37024 110515196
Hair texture abnormal 15.76 12.82 12 37067 3942 110548278
Jaw operation 15.74 12.82 7 37072 837 110551383
Diarrhoea 15.69 12.82 496 36583 1139009 109413211
Corneal degeneration 15.65 12.82 5 37074 239 110551981
Debridement 15.55 12.82 9 37070 1874 110550346
Encephalopathy 15.52 12.82 4 37075 81051 110471169
Actinomycosis 15.49 12.82 8 37071 1332 110550888
Medication error 15.46 12.82 8 37071 105358 110446862
Diabetic hyperosmolar coma 15.30 12.82 7 37072 895 110551325
Corneal disorder 15.28 12.82 10 37069 2587 110549633
Axillary lymphadenectomy 15.20 12.82 4 37075 95 110552125
Hypotension 15.18 12.82 108 36971 523741 110028479
Trigger finger 15.10 12.82 13 37066 5079 110547141
Breath odour 15.08 12.82 9 37070 1983 110550237
Haemangioma of liver 15.00 12.82 8 37071 1422 110550798
Adenocarcinoma 14.92 12.82 12 37067 4268 110547952
Cutaneous sarcoidosis 14.90 12.82 6 37073 561 110551659
Benign lymph node neoplasm 14.90 12.82 3 37076 20 110552200
Osteoarthritis 14.77 12.82 24 37055 182599 110369621
Red blood cell sedimentation rate increased 14.73 12.82 4 37075 78298 110473922
Anorectal disorder 14.73 12.82 10 37069 2749 110549471
Glioblastoma multiforme 14.69 12.82 8 37071 1482 110550738
Drug abuse 14.65 12.82 23 37056 177388 110374832
Erysipelas 14.64 12.82 20 37059 13138 110539082
Intentional product use issue 14.63 12.82 39 37040 247867 110304353
Oestradiol increased 14.61 12.82 4 37075 111 110552109
Product use in unapproved indication 14.59 12.82 89 36990 447288 110104932
Peripheral venous disease 14.56 12.82 5 37074 84112 110468108
Skeletal injury 14.47 12.82 8 37071 1527 110550693
Coma 14.46 12.82 11 37068 117858 110434362
Hallucination 14.44 12.82 8 37071 101424 110450796
Femur fracture 14.39 12.82 40 37039 44429 110507791
Contusion 14.32 12.82 36 37043 233325 110318895
Atypical fracture 14.27 12.82 7 37072 1045 110551175
Injection site reaction 14.24 12.82 6 37073 89064 110463156
Chronic myelomonocytic leukaemia 14.20 12.82 7 37072 1056 110551164
Respiratory failure 14.18 12.82 32 37047 215300 110336920
Biliary colic 14.17 12.82 12 37067 4585 110547635
Blood phosphorus increased 14.07 12.82 22 37057 16318 110535902
Ovarian granulosa-theca cell tumour 14.01 12.82 3 37076 28 110552192
Corneal graft rejection 13.97 12.82 4 37075 131 110552089
Coagulation factor V level decreased 13.82 12.82 6 37073 677 110551543
Pneumonia aspiration 13.77 12.82 5 37074 81228 110470992
Chronic obstructive pulmonary disease 13.63 12.82 10 37069 109148 110443072
Sciatica 13.58 12.82 7 37072 92392 110459828
Renal neoplasm 13.52 12.82 9 37070 2397 110549823
Blood potassium abnormal 13.48 12.82 11 37068 3994 110548226
Migraine 13.47 12.82 23 37056 171629 110380591
Enterocolitis bacterial 13.43 12.82 6 37073 725 110551495
Metastases to muscle 13.41 12.82 5 37074 380 110551840
Oestrogen receptor assay positive 13.39 12.82 5 37074 382 110551838
Mouth ulceration 13.37 12.82 41 37038 48097 110504123
Therapeutic product effect incomplete 13.37 12.82 35 37044 223770 110328450
Oral mucosal hypertrophy 13.32 12.82 3 37076 36 110552184
Bone cancer 13.30 12.82 9 37070 2461 110549759
Portal vein thrombosis 13.26 12.82 14 37065 7044 110545176
Brachiocephalic artery stenosis 13.24 12.82 3 37076 37 110552183
Rapidly progressive osteoarthritis 13.24 12.82 3 37076 37 110552183
Lower respiratory tract infection 13.06 12.82 40 37039 243066 110309154
Chronic hepatic failure 13.02 12.82 7 37072 1264 110550956
Toxic cardiomyopathy 12.99 12.82 6 37073 783 110551437
Autoimmune disorder 12.99 12.82 3 37076 65480 110486740
Adenoid cystic carcinoma 12.96 12.82 3 37076 41 110552179
Weight increased 12.90 12.82 85 36994 419559 110132661
Suspected counterfeit product 12.87 12.82 6 37073 800 110551420
Gastric infection 12.87 12.82 11 37068 4255 110547965
Peripheral swelling 12.85 12.82 81 36998 403953 110148267

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-estrogens
FDA MoA N0000000168 Selective Estrogen Receptor Modulators
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D020845 Selective Estrogen Receptor Modulators
MeSH PA D050071 Bone Density Conservation Agents
FDA EPC N0000175826 Estrogen Agonist/Antagonist
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:149553 anticoronaviral agent
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:37700 EC 2.7.11.13 (protein kinase C) inhibitor
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:50739 estrogen receptor modulator
CHEBI has role CHEBI:50792 estrogen receptor antagonist
CHEBI has role CHEBI:50837 estrogen antagonist
CHEBI has role CHEBI:62872 EC 1.2.3.1 (aldehyde oxidase) inhibitor
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

L02BA Anti-estrogens 3 drugs
elacestrantfulvestranttoremifene

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infiltrating duct carcinoma of breast indication 408643008 DOID:3008
Carcinoma of female breast indication 447782002
Prevention of Breast Carcinoma indication
Pain of breast off-label use 53430007
Endometrial carcinoma off-label use 254878006 DOID:2871
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercalcemia contraindication 66931009 DOID:12678
Leukopenia contraindication 84828003 DOID:615
Bilateral cataracts contraindication 95722004
Deep venous thrombosis contraindication 128053003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor MODULATOR Ki 7.51 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.00 DRUG MATRIX
Prostaglandin G/H synthase 2 Enzyme IC50 4.46 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 5.36 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.15 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.37 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.34 DRUG MATRIX
Adenosine receptor A2a GPCR Ki 5.40 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.14 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.50 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.80 CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 8.30 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 7 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.84 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.16 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.86 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.62 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.98 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 5.79 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.44 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.03 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.56 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.20 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.73 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.66 WOMBAT-PK
Beta-3 adrenergic receptor GPCR Ki 5.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.84 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.86 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.68 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor Ki 7.46 WOMBAT-PK
D(4) dopamine receptor GPCR Ki 5.41 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.61 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.20 DRUG MATRIX
Progesterone receptor Nuclear hormone receptor IC50 6.89 CHEMBL
Delta-type opioid receptor GPCR Ki 5.33 DRUG MATRIX
Estrogen receptor beta Nuclear hormone receptor IC50 5.91 WOMBAT-PK
G-protein coupled estrogen receptor 1 GPCR IC50 7.50 WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.45 DRUG MATRIX
Substance-P receptor GPCR Ki 5.07 DRUG MATRIX
Tyrosine-protein kinase Lck Kinase IC50 5.10 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.92 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.53 DRUG MATRIX
Glucosylceramidase Enzyme EC50 5.60 CHEMBL
Thromboxane-A synthase Enzyme IC50 6.04 DRUG MATRIX
Steroid hormone receptor ERR1 Nuclear hormone receptor IC50 6.70 CHEMBL
Substance-K receptor GPCR Ki 5.91 DRUG MATRIX
B2 bradykinin receptor GPCR Ki 4.92 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.53 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 4.60 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.76 DRUG MATRIX
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Enzyme IC50 4.52 DRUG MATRIX
Solute carrier family 22 member 2 Transporter IC50 4.06 WOMBAT-PK
Emopamil-binding protein-like Enzyme Ki 8.55 CHEMBL
Anti-estrogen binding site (AEBS) Enzyme Kd 9 CHEMBL
Estrogen-related receptor gamma Nuclear hormone receptor Ki 7.10 WOMBAT-PK
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 4.81 DRUG MATRIX
Androgen receptor Transcription factor Ki 4.82 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.42 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.59 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 4.66 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.92 CHEMBL
C-8 sterol isomerase Enzyme Ki 5.82 CHEMBL
Transcriptional activator protein luxR Transcription factor IC50 4.40 CHEMBL

External reference:

IDSource
4019939 VUID
N0000148024 NUI
D00966 KEGG_DRUG
54965-24-1 SECONDARY_CAS_RN
4018462 VANDF
4019939 VANDF
C0039286 UMLSCUI
CHEBI:41774 CHEBI
CHEMBL83 ChEMBL_ID
DB00675 DRUGBANK_ID
CHEMBL786 ChEMBL_ID
D013629 MESH_DESCRIPTOR_UI
2733526 PUBCHEM_CID
1016 IUPHAR_LIGAND_ID
3299 INN_ID
094ZI81Y45 UNII
10324 RXNORM
2281 MMSL
4270 MMSL
5540 MMSL
d00381 MMSL
002670 NDDF
004826 NDDF
373345002 SNOMEDCT_US
41395001 SNOMEDCT_US
75959001 SNOMEDCT_US
CTX PDB_CHEM_ID
094ZI81Y45 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0144 TABLET 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0144 TABLET 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0274 TABLET 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0274 TABLET 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2472 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2473 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0485 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0942 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0942 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-642 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-642 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-643 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-643 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
SOLTAMOX HUMAN PRESCRIPTION DRUG LABEL 1 51862-682 LIQUID 20 mg ORAL NDA 33 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-3004 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-4287 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate Human Prescription Drug Label 1 59651-299 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Tamoxifen Citrate Human Prescription Drug Label 1 59651-300 TABLET, FILM COATED 20 mg ORAL ANDA 24 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63187-976 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63739-269 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68071-3494 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68071-3990 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 68071-5254 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2208 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2209 TABLET, FILM COATED 20 mg ORAL ANDA 24 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 72162-2225 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 75907-058 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 75907-059 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections